OptimizeRx (NASDAQ:OPRX) Upgraded by Wall Street Zen to “Strong-Buy” Rating

OptimizeRx (NASDAQ:OPRX) was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday.

Other equities research analysts have also issued reports about the stock. Roth Capital restated a “buy” rating on shares of OptimizeRx in a report on Friday, August 8th. Stifel Nicolaus lifted their target price on OptimizeRx from $16.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, August 8th. Citizens Jmp raised their price target on shares of OptimizeRx from $23.00 to $24.00 and gave the stock a “market outperform” rating in a research note on Friday. UBS Group set a $23.00 target price on shares of OptimizeRx in a research report on Friday, October 10th. Finally, JMP Securities boosted their price target on shares of OptimizeRx from $20.00 to $23.00 and gave the stock a “market outperform” rating in a research report on Friday, October 10th. Nine analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $14.45.

OptimizeRx Trading Down 17.4%

Shares of OptimizeRx stock traded down $3.29 during trading hours on Friday, hitting $15.65. The company’s stock had a trading volume of 1,013,794 shares, compared to its average volume of 372,301. The company has a market capitalization of $290.54 million, a PE ratio of -28.98 and a beta of 1.24. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.57 and a quick ratio of 2.57. The stock has a 50 day moving average of $18.87 and a 200 day moving average of $15.10. OptimizeRx has a 12 month low of $3.78 and a 12 month high of $22.25.

OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.17. The business had revenue of $26.07 million during the quarter, compared to analyst estimates of $23.83 million. OptimizeRx had a positive return on equity of 4.50% and a negative net margin of 9.42%. OptimizeRx has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. Analysts predict that OptimizeRx will post -0.33 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Patrick D. Spangler sold 11,120 shares of the stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $17.49, for a total value of $194,488.80. Following the transaction, the director directly owned 44,215 shares of the company’s stock, valued at $773,320.35. This represents a 20.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Stephen L. Silvestro sold 1,620 shares of the firm’s stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $18.75, for a total transaction of $30,375.00. Following the sale, the chief executive officer owned 188,916 shares of the company’s stock, valued at approximately $3,542,175. This represents a 0.85% decrease in their position. The SEC filing for this sale provides additional information. 5.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On OptimizeRx

Hedge funds have recently bought and sold shares of the stock. Whetstone Capital Advisors LLC boosted its holdings in shares of OptimizeRx by 11.7% during the first quarter. Whetstone Capital Advisors LLC now owns 1,508,303 shares of the company’s stock worth $13,062,000 after acquiring an additional 157,880 shares during the period. Vanguard Group Inc. lifted its holdings in OptimizeRx by 15.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,059,109 shares of the company’s stock worth $21,712,000 after purchasing an additional 138,224 shares during the last quarter. Blair William & Co. IL boosted its stake in OptimizeRx by 4.9% in the 1st quarter. Blair William & Co. IL now owns 631,031 shares of the company’s stock valued at $5,465,000 after purchasing an additional 29,648 shares during the period. Parkman Healthcare Partners LLC acquired a new position in OptimizeRx in the 1st quarter valued at $4,114,000. Finally, Manatuck Hill Partners LLC increased its position in OptimizeRx by 139.5% during the 2nd quarter. Manatuck Hill Partners LLC now owns 455,000 shares of the company’s stock worth $6,142,000 after buying an additional 265,000 shares during the period. 76.47% of the stock is currently owned by institutional investors and hedge funds.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.